Prediction of metabolic drug clearance in humans: In vitro-in vivo extrapolation vs allometric scaling

Xenobiotica

Volumn 36, Issue 7, 2006, Pages 567-580

  Shiran, M R ^a,c   Proctor, N J ^b   Howgate, E M ^b   Rowland Yeo, K ^b   Tucker, G T ^a,b   Rostami Hodjegan, A ^a,b,d  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b CERTARA UK LIMITED   (United Kingdom)

^c MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Allometric scaling; In vitro in vivo correlation; Metabolic clearance; Pre clinical drug development

Indexed keywords

ALPRAZOLAM; CAFFEINE; CLOZAPINE; CYCLOSPORIN; CYTOCHROME P450; DEXTROMETHORPHAN; DICLOFENAC; MIDAZOLAM; OMEPRAZOLE; SILDENAFIL; THEOPHYLLINE; TOLBUTAMIDE; TOLTERODINE;

ACCURACY; ALLOMETRY; ARTICLE; BODY SURFACE; BODY WEIGHT; BRAIN WEIGHT; CORRELATION COEFFICIENT; DATA ANALYSIS; DRUG CLEARANCE; LIFESPAN; NONHUMAN; PREDICTION; RATING SCALE; RELIABILITY;

ANIMALS; DOGS; DRUG EVALUATION, PRECLINICAL; HUMANS; MICE; PHARMACEUTICAL PREPARATIONS; RATS;

ANIMALIA;

EID: 33746829030     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250600761662     Document Type: Article

References (117)

1. Abelo A, Andersson TB, Antonsson M, Naudot AK, Skanberg I, Weidolf L. 2000. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metabolism and Disposition 28:966-972.
2. Allonen H, Ziegler G, Klotz U. 1981. Midazolam kinetics. Clinical Pharmacology and Therapy 30:653-661.
3. Amchin J, Zarycranski W, Taylor KP, Albano D, Klockowski PM. 1998. Effect of venlafaxine on the pharmacokinetics of alprazolam. Psychopharmacology Bulletin 34:211-219.
4. Andersson T, Andren K, Cederberg C, Lagerstrom PO, Lundborg P, Skanberg I. 1990b. Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. British Journal of Clinical Pharmacology 29:557-563.
5. Andersson T, Cederberg C, Regardh CG, Skanberg I. 1990a. Pharmacokinetics of various single intravenous and oral doses of omeprazole. European Journal of Clinical Pharmacology 39:195-197.
6. Bachmann K. 1989. Predicting toxicokinetic parameters in humans from toxicokinetic data acquired from three small mammalian species. Journal of Applied Toxicology 9:331-338.
7. Bae HY, Choi DH, Choi JS. 2002. Pharmacokinetics of tolbutamide after oral administration in rabbits with folate-induced renal failure. Research Communications in Molecular Pathology and Pharmacology 111:237-244.
8. Birkett DJ, Miners JO. 1991. Caffeine renal clearance and urine caffeine concentrations during steady state dosing. Implications for monitoring caffeine intake during sports events. British Journal of Clinical Pharmacology 31:405-408.
9. Bonate PL, Howard D. 2000. Critique of prospective allometric scaling: Does the emperor have clothes? Journal of Clinical Pharmacology 40:345-346.
10. Bonati M, Latini R, Tognoni G, Young JF, Garattini S. 1984. Interspecies comparison of in vivo caffeine pharmacokinetics in man, monkey, rabbit, rat, and mouse. Drug Metabolism Reviews 15:1355-1383.
11. Boxenbaum H. 1982. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. Journal of Pharmacokinetics and Biopharmacology 10:201-227.
12. Boxenbaum H. 1984. Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metabolism Reviews 15:1071-1121.
13. Brynne N, Dalen P, Alvan G, Bertilsson L, Gabrielsson J. 1998. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Clinical Pharmacology and Therapy 63:529-539.
14. Brynne N, Svanstrom C, Aberg-Wistedt A, Hallen B, Bertilsson L. 1999. Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance. British Journal of Clinical Pharmacology 48:553-563.
15. Carrillo JA, Christensen M, Ramos SI, Alm C, Dahl ML, Benitez J, Bertilsson L. 2000. Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine. Therapy and Drug Monitoring 22:409-417.
16. Chappell WR, Mordenti J. 1991. Extrapolation of toxicological and pharmacological data from animals to human. Advances in Drug Research 20:2-116.
17. Chiou WL, Robbie G, Chung SM, Wu TC, Ma C. 1998. Correlation of plasma clearance of 54 extensively metabolized drugs between humans and rats: Mean allometric coefficient of 0.66. Pharmacology Research 15:1474-1479.
18. Delaporte E, Slaughter DE, Egan MA, Gatto GJ, Santos A, Shelley J, Price E, Howells L, Dean DC, Rodrigues AD. 2001. The potential for CYP2D6 inhibition screening using a novel scintillation proximity assay-based approach. Journal of Biomolecular Screening 6:225-231.
19. Ducharme MP, Warbasse LH, Edwards DJ. 1995a. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clinical Pharmacology and Therapy 57:485-491.
20. Eiermann B, Engel G, Johansson I, Zanger UM, Bertilsson L. 1997. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. British Journal of Clinical Pharmacology 44:439-446.
21. Friedman H, Redmond DE, Greenblatt DJ. 1991. Comparative pharmacokinetics of alprazolam and lorazepam in humans and in African Green Monkeys. Psychopharmacology (Berlin) 104:103-105.
22. Gascon AR, Calvo B, Hernandez RM, Dominguez-Gil A, Pedraz JL. 1994. Interspecies scaling of cimetidine-theophylline pharmacokinetic interaction: Interspecies scaling in pharmacokinetic interactions. Pharmacology Research 11:945-950.
23. Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA. 1994. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochemistry and Pharmacology 47:1643-1653.
24. Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, Shader RI. 1984. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 61:27-35.
25. Greenblatt DJ, Harmatz JS, Dorsey C, Shader RI. 1988. Comparative single-dose kinetics and dynamics of lorazepam, alprazolam, prazepam, and placebo. Clinical Pharmacology and Therapy 44:326-334.
26. Greenblatt DJ, Von Moltke LL, Harmatz JS, Durol AL, Daily JP, Graf JA, Mertzanis P, Hoffman JL, Shader RI. 2000a. Alprazolam-ritonavir interaction: Implications for product labeling. Clinical Pharmacology and Therapy 67:335-341.
27. Greenblatt DJ, Wright CE, Von Moltke LL, Harmatz JS, Ehrenberg BL, Harrel LM, Corbett K, Counihan M, Tobias S, Shader RI. 1998a. Ketoconazole inhibition of triazolam and alprazolam clearance: Differential kinetic and dynamic consequences. Clinical Pharmacology and Therapy 64:237-247.
28. Grevel J, Nuesch E, Abisch E, Kutz K. 1986. Pharmacokinetics of oral cyclosporin A (Sandimmun) in healthy subjects. European Journal of Clinical Pharmacology 31:211-216.
29. Ha HR, Chen J, Krahenbuhl S, Follath F. 1996. Biotransformation of caffeine by cDNA-expressed human cytochromes P-450. European Journal of Clinical Pharmacology 49:309-315.
30. Hagg S, Spigset O, Mjorndal T, Dahlqvist R. 2000. Effect of caffeine on clozapine pharmacokinetics in healthy volunteers. British Journal of Clinical Pharmacology 49:59-63.
31. Hamaoka N, Oda Y, Hase I, Mizutani K, Nakamoto T, Ishizaki T, Asada A. 1999. Propofol decreases the clearance of midazolam by inhibiting CYP3A4: An in vivo and in vitro study. Clinical Pharmacology and Therapy 66:110-117.
32. Heizmann P, Eckert M, Ziegler WH. 1983. Pharmacokinetics and bioavailability of midazolam in man. British Journal of Clinical Pharmacology 16(Suppl. 1):43S-49S.
33. Hirota N, Ito K, Iwatsubo T, Green CE, Tyson CA, Shimada N, Suzuki H, Sugiyama Y. 2001. In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans. Biopharmacology and Drug Disposition 22:53-71.
34. Houston JB, Carlile DJ. 1997. Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metabolism Reviews 29:891-922.
35. Howgate EM, Rowland-Yeo K, Proctor NJ, Tucker GT, Rostami-Hodjegan A. 2006. Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability. Xenobiotica 36:473-497.
36. Hyland R, Roe EG, Jones BC, Smith DA. 2001. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. British Journal of Clinical Pharmacology 51:239-248.
37. Ibrahim A, Karim A, Feldman J, Kharasch E. 2002. The influence of parecoxib, a parenteral cyclooxygenase-2 specific inhibitor, on the pharmacokinetics and clinical effects of midazolam. Anesthesia and Analgesics 95:667-673.
38. Inoue SI, Howgate EM, Rowland-Yeo K, Shimada T, Yamazaki H, Tucker GT, Rostami-Hodjegan A. 2006. Prediction of in vivo drug clearance from in vitro data. II: Potential inter-ethnic differences. Xenobiotica 36: 499-513.
39. Iwata H, Fujita K, Kushida H, Suzuki A, Konno Y, Nakamura K, Fujino A, Kamataki T. 1998. High catalytic activity of human cytochrome P450 co-expressed with human NADPH-cytochrome P450 reductase in Escherichia coli. Biochemistry and Pharmacology 55:1315-1325.
40. Johnson TN, Rostami-Hodjegan A, Tucker GT. 2006. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clinical Pharmacokinetics (in press).
41. Kaplan GB, Greenblatt DJ, Ehrenberg BL, Goddard JE, Harmatz JS, Shader RI. 1998. Single-dose pharmacokinetics and pharmacodynamics of alprazolam in elderly and young subjects. Journal of Clinical Pharmacology 38:14-21.
42. Karam WG, Goldstein JA, Lasker JM, Ghanayem BI. 1996. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metabolism and Disposition 24:1081-1087.
43. Keldenich J. 2004. Prediction of human clearance (CL) and volume of distribution (VD). Drug Discovery Today: Technologies 1:389-395.
44. Kirchheiner J, Bauer S, Meineke I, Rohde W, Prang V, Meisel C, Roots I, Brockmoller J. 2002. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics 12:101-109.
45. Kirkwood C, Moore A, Hayes P, DeVane CL, Pelonero A. 1991. Influence of menstrual cycle and gender on alprazolam pharmacokinetics. Clinical Pharmacology and Therapy 50:404-409.
46. Klotz U, Ziegler G. 1982. Physiologic and temporal variation in hepatic elimination of midazolam. Clinical Pharmacology and Therapy 32:107-112.
47. Knodell RG, Hall SD, Wilkinson GR, Guengerich FP. 1987. Hepatic metabolism of tolbutamide: Characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. Journal of Pharmacology and Experimental Therapy 241:1112-1119.
48. Kukanich B, Papich MG. 2004. Plasma profile and pharmacokinetics of dextromethorphan after intravenous and oral administration in healthy dogs. Journal of Veterinary and Pharmacology Therapy 27:337-341.
49. Lasker JM, Wester MR, Aramsombatdee E, Raucy JL. 1998. Characterization of CYP2C19 and CYP2C9 from human liver: Respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Archives of Biochemistry and Biophysics 353:16-28.
50. Lave T, Coassol P, Reigner B. 1999. Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations. Clinical Pharmacokinetics 36:211-231.
51. Lave T, Dupin S, Schmitt C, Chou RC, Jaeck D, Coassolo P. 1997. Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: Application to 10 extensively metabolized drugs. Journal of Pharmacology Science 86:584-590.
52. Lee CR, Pieper JA, Hinderliter AL, Blaisdell JA, Goldstein JA. 2002. Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes. Clinical Pharmacology and Therapy 72:562-571.
53. Lin KM, Lau JK, Smith R, Phillips P, Antal E, Poland RE. 1988. Comparison of alprazolam plasma levels in normal Asian and Caucasian male volunteers. Psychopharmacology (Berlin) 96:365-369.
54. Linnet K, Olesen OV. 1997. Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes. Drug Metabolism and Disposition 25:1379-1382.
55. Liu XD, Chen J. 2001. Prediction of drug clearance in humans from laboratory animals based on body surface area. European Journal of Drug Metabolism Pharmacokinetics 26:249-255.
56. Madsen H, Enggaard TP, Hansen LL, Klitgaard NA, Brosen K. 2001. Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. Clinical Pharmacology and Therapy 69:41-47.
57. Mahmood I. 2002a. Interspecies scaling: Predicting oral clearance in humans. American Journal of Therapy 9:35-42.
58. Mahmood I. 2002b. Prediction of clearance in humans from in vitro human liver microsomes and allometric scaling. A comparative study of the two approaches. Drug Metabolism Drug Interactions 19:49-64.
59. Mahmood I, Balian JD. 1996. Interspecies scaling: A comparative study for the prediction of clearance and volume using two or more than two species. Life Sciences 59:579-585.
60. Mahmood I, Balian JD. 1996. Interspecies scaling: Predicting clearance of drugs in humans. Three different approaches. Xenobiotica 26:887-895.
61. Mahmood I, Balian JD. 1996. Interspecies scaling: Predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance. Journal of Pharmacology Science 85:411-414.
62. Mahmood I, Balian JD. 1999. The pharmacokinetic principles behind scaling from preclinical results to phase I protocols. Clinical Pharmacokinetics 36:1-11.
63. Mankowski DC, Lawton MP, Ekins S. 2000. Characterization of transgenic mouse strains using six human hepatic cytochrome P450 probe substrates. Xenobiotica 30:745-754.
64. Mehl ML, Kyles AE, Craigmill AL, Epstein S, Gregory CR. 2003. Disposition of cyclosporine after intravenous and multi-dose oral administration in cats. Journal of Veterinary and Pharmacology Therapy 26:349-354.
65. Min DI, Lee M, Ku YM, Flanigan M. 2000. Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. Clinical Pharmacology and Therapy 68:478-486.
66. Miners JO, Wing LM, Lillywhite KJ, Smith KJ. 1984. Failure of 'therapeutic' doses of beta-adrenoceptor antagonists to alter the disposition of tolbutamide and lignocaine. British Journal of Clinical Pharmacology 18:853-860.
67. Moghadamnia AA, Rostami-Hodjegan A, Abdul-Manap R, Wright CE, Morice AH, Tucker GT. 2003. Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: Dextromethorphan vs. dextrorphan using quinidine inhibition. British Journal of Clinical Pharmacology 56:57-67.
68. Muirhead GJ, Rance DJ, Walker DK, Wastall P. 2002a. Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil. British Journal of Clinical Pharmacology 53:3S-20S.
69. Muirhead GJ, Wilner K, Colburn W, Haug-Pihale G, Rouviex B. 2002b. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. British Journal of Clinical Pharmacology 53:21S-30S.
70. Nagilla R, Frank KA, Jolivette LJ, Ward KW. 2006. Investigation of the utility of published in vitro intrinsic clearance data for prediction of in vivo clearance. Journal of Pharmacology Toxicology Methods 53:106-116.
71. Nagilla R, Ward KW. 2004. A comprehensive analysis of the role of correction factors in the allometric predictivity of clearance from rat, dog, and monkey to humans. Journal of Pharmacology Science 93:2522-2534.
72. Obach RS, Baxter JG, Liston TE, Silber BM, Jones C, Macintyre F, Rance DJ, Wastall P. 1997. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism. Journal of Pharmacology Experimental Therapy 283:46-58.
73. Oda Y, Mizutani K, Hase I, Nakamoto T, Hamaoka N, Asada A. 1999. Fentanyl inhibits metabolism of midazolam: Competitive inhibition of CYP3A4 in vitro. British Journal of Anaesthesia 82:900-903.
74. Pahlman I, Kankaanranta S, Palmer L. 2001. Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog. Interspecies relationship comparing with human pharmacokinetics. Arzneimittelforschung 51:134-144.
75. Palamanda J, Feng WW, Lin CC, Nomeir AA. 2000. Stimulation of tolbutamide hydroxylation by acetone and acetonitrile in human liver microsomes and in a cytochrome P-450 2C9-reconstituted system. Drug Metabolism and Disposition 28:38-43.
76. Peart GF, Boutagy J, Shenfield GM. 1987. Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype. European Journal of Clinical Pharmacology 33:397-402.
77. Peris-Ribera JE, Torres-Molina F, Garcia-Carbonell MC, Aristorena JC, Pla-Delfina JM. 1991. Pharmacokinetics and bioavailability of diclofenac in the rat. Journal of Pharmacokinetics and Biopharmacology 19:647-665.
78. Pichard L, Domergue J, Fourtanier G, Koch P, Schran HF, Maurel P. 1996. Metabolism of the new immunosuppressor cyclosporin G by human liver cytochromes P450. Biochemistry and Pharmacology 51:591-598.
79. Postlind H, Danielson A, Lindgren A, Andersson SH. 1998. Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metabolism and Disposition 26:289-293.
80. Proctor NJ, Tucker GT, Rostami-Hodjegan A. 2004. Predicting drug clearance from recombinantly expressed CYPs: Intersystem extrapolation factors. Xenobiotica 34:151-178.
81. Rane A, Wilkinson GR, Shand DG. 1977. Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. Journal of Pharmacology and Experimental Therapy 200:420-424.
82. Regardh CG, Andersson T, Lagerstrom PO, Lundborg P, Skanberg I. 1990. The pharmacokinetics of omeprazole in humans - a study of single intravenous and oral doses. Therapy and Drug Monitoring 12:163-172.
83. Regardh CG, Gabrielsson M, Hoffman KJ, Lofberg I, Skanberg I. 1985. Pharmacokinetics and metabolism of omeprazole in animals and man - an overview. Scandinavian Journal of Gastroenterology Suppl. 108:79-94.
84. Rowland-Yeo K, Rostami-Hodjegan A, Tucker GT. 2004. Abundance of cytochromes P450 in human liver: A meta-analysis. British Journal of Clinical Pharmacology 57:687.
85. Sangalli L, Bortolotti A, Jiritano L, Bonati M. 1988. Cyclosporine pharmacokinetics in rats and interspecies comparison in dogs, rabbits, rats, and humans. Drug Metabolism and Disposition 16:749-753.
86. Soto J, Alsar MJ. 1997. A pilot study of the effect of antipyrine on caffeine kinetics in six healthy volunteer subjects. Journal of Clinical Pharmacology and Therapy 22:191-195.
87. Steffan J, Strehlau G, Maurer M, Rohlfs A. 2004. Cyclosporin A pharmacokinetics and efficacy in the treatment of atopic dermatitis in dogs. Journal of Veterinary and Pharmacology Therapy 27:231-238.
88. Stein CM, Sadeque AJ, Murray JJ, Wandel C, Kim RB, Wood AJ. 2001. Cyclosporine pharmacokinetics and pharmacodynamics in African American and white subjects. Clinical Pharmacology and Therapy 69:317-323.
89. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA. 1996. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6:341-349.
90. Sun L, Lau CE. 2000. Intravenous and oral clozapine pharmacokinetics, pharmacodynamics, and concentration-effect relations: Acute tolerance. European Journal of Pharmacology 398:225-238.
91. Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, Chiba K. 2000. CYP2C9 Ile359 and Leu359 variants: Enzyme kinetic study with seven substrates. Pharmacogenetics 10:95-104.
92. Tallman MN, Ali SY, Smith PC. 2004. Altered pharmacokinetics of omeprazole in cystic fibrosis knockout mice relative to wild-type mice. Drug Metabolism and Disposition 32:902-925.
93. Tan KK, Trull AK, Shawket S. 1989. Co-administration of ciprofloxacin and cyclosporin: Lack of evidence for a pharmacokinetic interaction. British Journal of Clinical Pharmacology 28:185-187.
94. Tang W, Stearns RA, Kwei GY, Iliff SA, Miller RR, Egan MA, Yu NX, Dean DC, Kumar S, Shou M, Lin JH, Baillie TA. 1999. Interaction of diclofenac and quinidine in monkeys: Stimulation of diclofenac metabolism. Journal of Pharmacology and Experimental Therapy 291:1068-1074.
95. Tang H, Mayersohn M. 2005a. A novel model for prediction of human drug clearance by allometric scaling. Drug Metab Dispos 33:1297-1303.
96. Tang H, Mayersohn M. 2005b. A mathematical description of the functionality of correction factors used in allometry for predicting human drug clearance. Drug Metab Dispos 33:1294-1296.
97. Tang H, Mayersohn M. 2005c. Accuracy of allometrically predicted pharmacokinetic parameters in humans: role of species selection. Drug Metab Dispos 33:1288-1293.
98. Tantcheva-Poor I, Zaigler M, Rietbrock S, Fuhr U. 1999. Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. Pharmacogenetics 9:131-144.
99. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, Wilkinson GR. 1996. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clinical Pharmacology and Therapy 59:491-502.
100. Tremaine LM,Wilner KD, Preskorn SH. 1997. A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide. Clinical Pharmacokinetics 32:31-36.
101. Tsunoda SM, Harris RZ, Christians U, Velez RL, Freeman RB, Benet LZ, Warshaw A. 2001. Red wine decreases cyclosporine bioavailability. Clinical Pharmacology and Therapy 70:462-467.
102. Von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Venkatakrishnan K, Schmider J, Harmatz JS, Shader RI. 1998. Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: Role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. Journal of Pharmacology and Pharmaceutics 50:997-1004.
103. Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR. 2000. CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B 5′-promoter region polymorphism. Clinical Pharmacology and Therapy 68:82-91.
104. Wang RW, Newton DJ, Liu N, Atkins WM, Lu AY. 2000. Human cytochrome P-450 3A4: In vitro drug-drug interaction patterns are substrate-dependent. Drug Metabolism and Disposition 28:360-366.
105. Wang Y, Roy A, Sun L, Lau CE. 1999. A double-peak phenomenon in the pharmacokinetics of alprazolam after oral administration. Drug Metabolism and Disposition 27:855-859.
106. Warrington JS, Shader RI, Von Moltke LL, Greenblatt DJ. 2000. In vitro biotransformation of sildenafil (Viagra): Identification of human cytochromes and potential drug interactions. Drug Metabolism and Disposition 28:392-397.
107. Watanabe K, Matsuka N, Okazaki M, Hashimoto Y, Araki H, Gomita Y. 2002. The effect of immobilization stress on the pharmacokinetics of omeprazole in rats. Acta Medica Okayama 56:19-23.
108. Wietholtz H, Zysset T, Marschall HU, Generet K, Matern S. 1995. The influence of rifampin treatment on caffeine clearance in healthy man. Journal of Hepatology 22:78-81.
109. Wilson ZE, Rostami-Hodjegan A, Burn JL, Tooley A, Boyle J, Ellis SW, Tucker GT. 2003. Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. British Journal of Clinical Pharmacology 56:433-440.
110. Wong SL, Locke C, Staser J, Granneman GR. 1998. Lack of multiple dosing effect of sertindole on the pharmacokinetics of alprazolam in healthy volunteers. Psychopharmacology 135:236-241.
111. Yamao T, Nakagami H, Furuhama K, Onodera T, Kurosaki Y, Nakayama T, Kimura T. 1994. Pharmacokinetics of tolbutamide following intravenous and oral administrations in rats with obstructive jaundice. Biology and Pharmacology Bulletin 17:691-695.
112. Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP, Shimada T. 1997. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: Effects of contents of these two forms in individual human samples. Journal of Pharmacology and Experimental Therapy 283:434-442.
113. Yu A, Haining RL. 2001. Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: Can dextromethorphan be used as a dual probe for both CYP2D6 and CYP3A activities?. Drug Metabolism and Disposition 29:1514-1520.
114. Yu A, Dong H, Lang D, Haining RL. 2001. Characterization of dextromethorphan O- and N-demethylation catalyzed by highly purified recombinant human CYP2D6. Drug Metabolism and Disposition 29:1362-1365.
115. Zeng YL, Wang ZR, Lu ML. 1986. Pharmacokinetics of clozapine in rabbits. Yao Xue Xue Bao 21:566-571.
116. Zuegge J, Schneider G, Coassolo P, Lave T. 2001. Prediction of hepatic metabolic clearance: Comparison and assessment of prediction models. Clinical Pharmacokinetics 40:553-563.
117. Zysset T, Zeugin T, Kupfer A. 1988. In-vivo and in-vitro dextromethorphan metabolism in SD and DA rat. An animal model of the debrisoquine-type polymorphic oxidation in man. Biochemistry and Pharmacology 37:3155-3160.